A 12-page Executive Summary offering summary highlights for 22 Accountable Care Organizations and ACO solutions companies regarding their successes during the most recent MSSP performance year.
Five Highlights from Vizient's Drug Price Forecast Report
- Specialty drug price inflation is predicted to be 4.23 percent.
- The composition of the U.S. biosimilars market could change dramatically in the very near future.
- Drug shortages compromise patient care and contribute to higher costs
- both direct and indirect.
- Providers treating leukemia patients will experience higher costs as the standard of care shifts to new therapy combinations.
- Supply challenges in the Immune globulin intravenous (IgIV) market will continue and prices are expected to steadily rise.